^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Ovarian Cancer

    Related cancers:
    2d
    Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Thomas Jefferson University | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    2d
    ALS-6000-101: A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours (clinicaltrials.gov)
    P1, N=158, Recruiting, Avacta Life Sciences Ltd | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial primary completion date • First-in-human
    |
    BRCA (Breast cancer early onset) • FAP (Fibroblast activation protein, alpha)
    |
    BRCA wild-type
    |
    doxorubicin hydrochloride • faridoxorubicin (AVA6000)
    2d
    EB-DUALNK-OV: Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    3d
    DSB2455-001: Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies (clinicaltrials.gov)
    P1, N=180, Recruiting, Duke Street Bio Ltd | N=90 --> 180 | Trial completion date: Aug 2028 --> Dec 2028 | Trial primary completion date: Aug 2027 --> Aug 2028
    Enrollment change • Trial completion date • Trial primary completion date
    3d
    RESO: A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer (clinicaltrials.gov)
    P=N/A, N=500, Not yet recruiting, Zhejiang Cancer Hospital
    New trial • Real-world evidence
    |
    Paishuning (senaparib)
    3d
    N01-A-PICIT-GT: Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors (clinicaltrials.gov)
    P2, N=220, Recruiting, Peking University People's Hospital
    New P2 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3d
    5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial (clinicaltrials.gov)
    P2, N=170, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    3d
    F-IOTA: Fetal Ovarian Cysts and IOTA Terminology for Perinatal Management (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    New trial
    3d
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Peking University First Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CA9 (Carbonic anhydrase 9)
    4d
    MONITOR-UK: Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR (clinicaltrials.gov)
    P=N/A, N=388, Completed, Royal Marsden NHS Foundation Trust | Recruiting --> Completed | Trial completion date: Feb 2024 --> Apr 2026 | Trial primary completion date: Feb 2024 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Zejula (niraparib)
    4d
    NT-175-201: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
    P1, N=45, Recruiting, AstraZeneca | Trial primary completion date: Sep 2028 --> Jul 2029
    Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV • NT-175
    4d
    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)
    P1/2, N=460, Recruiting, Merck Sharp & Dohme LLC | N=280 --> 460
    Enrollment change
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • raludotatug deruxtecan (DS-6000)